ATE493129T1 - Depot formulierungen von iloperidone und einem sternförmigen polymer - Google Patents

Depot formulierungen von iloperidone und einem sternförmigen polymer

Info

Publication number
ATE493129T1
ATE493129T1 AT02785330T AT02785330T ATE493129T1 AT E493129 T1 ATE493129 T1 AT E493129T1 AT 02785330 T AT02785330 T AT 02785330T AT 02785330 T AT02785330 T AT 02785330T AT E493129 T1 ATE493129 T1 AT E493129T1
Authority
AT
Austria
Prior art keywords
iloperidone
star
shaped polymer
depot formulations
polymer
Prior art date
Application number
AT02785330T
Other languages
English (en)
Inventor
Markus Ahlheim
Rolf Loeffler
Original Assignee
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh
Application granted granted Critical
Publication of ATE493129T1 publication Critical patent/ATE493129T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
AT02785330T 2001-10-30 2002-10-29 Depot formulierungen von iloperidone und einem sternförmigen polymer ATE493129T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33903601P 2001-10-30 2001-10-30
PCT/EP2002/012073 WO2003037337A1 (en) 2001-10-30 2002-10-29 Depot formulations of iloperidone and a star polymer

Publications (1)

Publication Number Publication Date
ATE493129T1 true ATE493129T1 (de) 2011-01-15

Family

ID=23327202

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02785330T ATE493129T1 (de) 2001-10-30 2002-10-29 Depot formulierungen von iloperidone und einem sternförmigen polymer

Country Status (11)

Country Link
US (2) US7767230B2 (de)
EP (2) EP1441727B1 (de)
JP (1) JP5067998B2 (de)
CN (2) CN1578664A (de)
AT (1) ATE493129T1 (de)
BR (1) BRPI0213564B8 (de)
CA (1) CA2463158C (de)
CY (1) CY1111357T1 (de)
DE (1) DE60238780D1 (de)
ES (2) ES2358416T3 (de)
WO (1) WO2003037337A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60027730T2 (de) * 1999-09-09 2007-03-29 The Regents Of The University Of California, Oakland Verabreichung von taxanen an angiogene blutgefässe mittels kationischer liposomen
EP1441727B1 (de) * 2001-10-30 2010-12-29 Novartis AG Depot formulierungen von iloperidone und einem sternförmigen polymer
GB0216416D0 (en) * 2002-07-15 2002-08-21 Novartis Ag Organic compounds
JP2008514731A (ja) * 2004-09-30 2008-05-08 ヴァンダ ファーマシューティカルズ インコーポレイテッド イロペリドンの投与方法
US20100063093A1 (en) 2007-03-28 2010-03-11 Curt Wolfgang Methods for the administration of iloperidone
DE102005051342A1 (de) * 2005-10-25 2007-04-26 Goldschmidt Gmbh Verkapselung und kontrollierte Freisetzung biologisch aktiver Wirkstoffe mit enzymatisch abbaubaren hyperverzweigten Trägerpolymeren
JP5264492B2 (ja) 2005-10-25 2013-08-14 エボニック デグサ ゲーエムベーハー 超分岐ポリマーを含有する調製物
JP2009538331A (ja) 2006-05-22 2009-11-05 ヴァンダ ファーマシューティカルズ インコーポレイテッド 抑うつ障害のための治療
CN100460441C (zh) * 2006-09-25 2009-02-11 南开大学 生物可降解星型结构聚乙丙交酯载药微球及其制备方法
EP2236546B1 (de) 2006-10-31 2011-12-28 Surmodics Pharmaceuticals, Inc. Kugelförmige Polymer-Partikel
JP5653753B2 (ja) * 2007-09-10 2015-01-14 ヴァンダ ファーマシューティカルズ インコーポレイテッド Ｓｎｐ遺伝子型に基づくｑｔ延長の予測
WO2009076663A1 (en) 2007-12-13 2009-06-18 Vanda Pharmaceuticals Inc. Method and composition for treating an alpha adrenoceptor-mediated condition
PT2222300E (pt) 2007-12-13 2014-07-28 Vanda Pharmaceuticals Inc Método e composição para tratamento de uma condição mediada por recetores da serotonina
EP2453891A1 (de) 2009-07-16 2012-05-23 Vanda Pharmaceuticals Inc. Verwendung eines melatoninagonisten zur behandlung von schlafstörungen, u.a. primärer insomnie
BR112012015084A2 (pt) * 2009-12-23 2017-03-07 Lupin Ltd composição farmacêutica de liberação lenta de iloperidone
CN102311430A (zh) * 2010-06-29 2012-01-11 大道隆达（北京）医药科技发展有限公司 伊潘立酮的新晶态及其制备方法
WO2012123963A2 (en) * 2011-02-24 2012-09-20 Megafine Pharma (P) Ltd. A process for preparation of iloperidone and amorphous co- precipitate of iloperidone with pharmaceutically acceptable excipient
US11918557B2 (en) 2012-01-26 2024-03-05 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
DK2806863T3 (en) 2012-01-26 2017-10-30 Vanda Pharmaceuticals Inc Treatment of circadian rhythm disorders
CN108997160A (zh) 2012-05-18 2018-12-14 万达制药公司 （1r-反）-n-[[2-（2,3-二氢-4-苯并呋喃基）环丙基]甲基]丙酰胺代谢物
KR102148990B1 (ko) 2012-12-18 2020-08-27 반다 파마슈티칼즈, 인코퍼레이티드. 일주기 리듬 장애의 치료
US10376487B2 (en) 2013-11-12 2019-08-13 Vanda Pharmaceuticals Inc. Method of treatment
US11090285B2 (en) 2013-11-12 2021-08-17 Vanda Pharmaceuticals Inc Treatment of circadian rhythm disorders
CN103599074A (zh) * 2013-11-26 2014-02-26 重庆医药工业研究院有限责任公司 一种伊潘立酮缓释微球及其制备方法
CN104352443A (zh) * 2014-10-21 2015-02-18 河北科技大学 伊潘立酮缓释微球及其制备方法
EP3258935B1 (de) 2015-02-17 2021-04-07 Vanda Pharmaceuticals Inc. Loperidon zur behandlung von schizophrenie
US11071728B2 (en) 2015-12-11 2021-07-27 Vanda Pharmaceuticals Inc. Treatment of schizophrenia
WO2020117901A1 (en) * 2018-12-04 2020-06-11 Vanda Pharmaceuticals Inc. Depot administration of iloperidone
GB201900258D0 (en) 2019-01-08 2019-02-27 Medincell Pharmaceutical composition
US11607408B2 (en) 2019-10-15 2023-03-21 Vanda Pharmaceuticals Inc. Method of treatment of schizophrenia
WO2024137439A1 (en) 2022-12-19 2024-06-27 Vanda Pharmaceuticals Inc. Dosage regime of iloperidone for treating bipolar i disorder and schizophrenia

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH656884A5 (de) 1983-08-26 1986-07-31 Sandoz Ag Polyolester, deren herstellung und verwendung.
DE3511587A1 (de) * 1985-03-27 1986-10-02 Schering AG, Berlin und Bergkamen, 1000 Berlin Glykoester des estradiols und estriols
US4886370A (en) 1987-08-25 1989-12-12 Nkk Corporation Method for detecting a state of substance existing in pipe
US5776963A (en) * 1989-05-19 1998-07-07 Hoechst Marion Roussel, Inc. 3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility
US5364866A (en) 1989-05-19 1994-11-15 Hoechst-Roussel Pharmaceuticals, Inc. Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analetics
EP0402644B1 (de) * 1989-05-19 1995-08-16 Hoechst-Roussel Pharmaceuticals Incorporated N-(aryloxyalkyl)heteroarylpiperidine und -heteroarylpiperazine, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikamente
US5538739A (en) 1989-07-07 1996-07-23 Sandoz Ltd. Sustained release formulations of water soluble peptides
AU636043B2 (en) * 1990-06-04 1993-04-08 Schering Corporation Method for preparing interferon alpha-2 crystals
SG47445A1 (en) * 1993-11-19 1998-04-17 Janssen Pharmaceutica Nv Microencapsulated 3-piperidinyl-substituted1 1 2-benzisoxazoles and 1 2-benzisothiazoles
BR9809162A (pt) 1997-05-26 2000-08-01 Akzo Nobel Nv Sal de trans-5-cloro-2, 3, 3a, 12b-tetrahidro-2-metil-1h-dibenz [2,3:6,7] oxepino[4,5-c] pirrol e agente formador de sal, composto, composição farmacêutica, e, preparação de injeção armazenável
UA72189C2 (uk) * 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
US5955459A (en) * 1997-11-26 1999-09-21 Neuromedica, Inc. Fatty acid-antipsychotic compositions and uses thereof
US6541606B2 (en) * 1997-12-31 2003-04-01 Altus Biologics Inc. Stabilized protein crystals formulations containing them and methods of making them
DE19816070A1 (de) 1998-04-09 1999-10-14 Aventis Res & Tech Gmbh & Co Retardtablette hergestellt aus linearen wasserunlöslichen Polysacchariden
EE200100136A (et) * 1998-10-16 2002-06-17 Janssen Pharmaceutica N.V. Atsetüülkoliini esteraasi inhibiitori ja psühhoosivastase toimeaine kasutamine ravimi valmistamiseks, mis on ette nähtud kognitsiooni- ja psühhoosihäirete raviks, ning neid aineid sisaldav farmatseutiline kompositsioon
WO2001092334A1 (en) 2000-06-02 2001-12-06 Novo Nordisk A/S Glucose dependent release of insulin from glucose sensing insulin derivatives
DK2305656T3 (da) 2001-08-31 2013-02-11 Novartis Ag Optiske isomerer of en iloperidonmetabolit
EP1441727B1 (de) * 2001-10-30 2010-12-29 Novartis AG Depot formulierungen von iloperidone und einem sternförmigen polymer
GB0216416D0 (en) 2002-07-15 2002-08-21 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
JP5067998B2 (ja) 2012-11-07
EP1441727B1 (de) 2010-12-29
CY1111357T1 (el) 2015-08-05
DE60238780D1 (de) 2011-02-10
EP1441727A1 (de) 2004-08-04
US7767230B2 (en) 2010-08-03
WO2003037337A8 (en) 2004-05-13
EP2295058B1 (de) 2013-09-04
US20100233217A1 (en) 2010-09-16
CN101912367A (zh) 2010-12-15
ES2358416T3 (es) 2011-05-10
US8815293B2 (en) 2014-08-26
EP2295058A1 (de) 2011-03-16
CA2463158C (en) 2013-07-30
CA2463158A1 (en) 2003-05-08
WO2003037337A1 (en) 2003-05-08
JP2005508975A (ja) 2005-04-07
ES2436439T3 (es) 2014-01-02
HK1155381A1 (en) 2012-05-18
HK1068263A1 (en) 2005-04-29
BRPI0213564B1 (pt) 2016-08-02
BRPI0213564B8 (pt) 2021-05-25
CN1578664A (zh) 2005-02-09
US20030091645A1 (en) 2003-05-15
BR0213564A (pt) 2004-08-31

Similar Documents

Publication Publication Date Title
ATE493129T1 (de) Depot formulierungen von iloperidone und einem sternförmigen polymer
DE60235083D1 (de) Substituierte tetracyclin-verbindungen zur behandlung von malaria
ATE282653T1 (de) Saure polymilchsäure polymere
DE69812946D1 (de) Ethylenpolymerzusammensetzungen und daraus hergestellte gegenstände
DE69728307D1 (de) Absorbierbare polymer Mischungen und chirurgische Gegenstände daraus
EP1852437A3 (de) 42-O-Alkoxyalkyl-Rapamycin-Derivate und Zusammensetzungen damit
ATE504562T1 (de) 7-, 8- und 9-substitutierte tetracyclinverbindungen
EP1233956A4 (de) Bryostatin analoga, synthetische methoden und verwendungen
AU2001259651A1 (en) Polymers containing oxygen and sulfur alicyclic units and photoresist compositions comprising same
DE69626589D1 (de) Polymer, Verfahren zur Herstellung, Haarbehandlungszusammensetzungen und kosmetische Zusammensetzungen
DE69923359D1 (de) Zusammensetzungen und daraus hergestellte gegenstände
ATE296642T1 (de) Reverse-phase zusamensetzung zur bindegewebsreparatur
DE60113121T2 (de) Herstellung von vernetzter Hyaluronsäure und dessen Hydrogel, daraus hergestellte Produkte und deren Verwendung
WO2004042797A3 (en) Sacrificial compositions, methods of use thereof, and methods of decomposition thereof
ATE353675T1 (de) Kationische-alkid-polyester für medizinische anwendungen
DE60322824D1 (de) Funktionalisierte Alkydpolyesterpolymere zur medizinischen Verwendung
ID15948A (id) Komposisi-komposisi insektisida berdasarkan polimer-polimer
DE60020206D1 (de) Zusammensetzung und Verfahren zur Herstellung von dehnbaren Polymeren und dadurch geformte Gegenstände
DE60214853D1 (de) Biologisch abbaubare kaugummigrundmasse
EP2377519A3 (de) Arzneimittel enthaltend Octreotidmikropartikel
DE60120416D1 (de) Polyaminoestern und deren verwendung zur herstellung von dentalmassen
DE69132415D1 (de) Umweltfreundliche Polymerzusammensetzungen sowie Anwendungen desselben
DE69705108D1 (de) Mischungen ausgehend von eugenia jambolana lamarck samen, herstellung und verwendung solcher mischungen sowie einiger inhaltsstoffe als medikamente
DK1071483T3 (da) Knogleimplantat
DE60234756D1 (de) Konjugierte homo- und copolymere enthaltend substituierte oder unsubstituierte heteroaryleinheiten, herstellung und verwendung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1441727

Country of ref document: EP